• Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues – Archives
  • Subscribe
  • Contact
Facebook Twitter Instagram
Trending
  • CDC Boss kicked out in RFK Jr.’s War on Corruption in pharma and healthcare
  • Prof. Rajeev Varshney FRS, now joins Australian Academy of Science
  • Dr. Cyrus S. Poonawalla, SII unveiled the newly built School for Hearing Impaired in Pune
  • AdFalciVax: ICMR’s New Malaria Vaccine: Hope or Premature Hype?”
  • The Sudden Deaths and COVID Vaccines: A Critical Analysis of the ICMR and AIIMS Studies
  • KGMU Scandal: Dr. Tulika Chandra Exposed in Crore Rupee Forgery and Scam
  • Zydus to launch market-specific dosage variants of Semaglutide, MD says
  • Biocon Biologics Launches Nepexto, Etanercept Biosimilar in Australia
Wednesday, October 1
Facebook Twitter Instagram LinkedIn
Biotech Express
  • Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    04/01/20241

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    Recent
    04/01/2024

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    22/05/2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    26/07/2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

  • Issues – Archives
  • Subscribe
  • Contact
Biotech Express
You are at:Home»Biotech News»News-Industry»USFDA approves Biocon Biologics’ biosimilar for Crohn’s disease, psoriasis

USFDA approves Biocon Biologics’ biosimilar for Crohn’s disease, psoriasis

0
By Biotech Express on 01/12/2024 News-Industry

Biocon’s arm, Biocon Biologics Ltd (BBL), announced today that the US Food and Drug Administration (USFDA) has approved YESINTEK (Ustekinumab-kfce), a biosimilar to the reference product Stelara (Ustekinumab), according to a company filing.

YESINTEK, a monoclonal antibody, is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

Shreehas Tambe, chief executive officer and managing director of Biocon Biologics, said, “This settlement agreement reflects our commitment and focus on science and innovation. We are pleased that this allows Biocon Biologics to be among the first to offer a reliable, high-quality biosimilar option to patients and healthcare providers in the United States with our bUstekinumab, Bmab 1200. This development enables Biocon Biologics to build further on our existing immunology franchise in the US. As a fully integrated biosimilars company, Biocon Biologics is committed to expanding access to life-changing treatments with our broad portfolio of products.”

Matthew Erick, chief commercial officer for advanced markets at Biocon Biologics, noted that the agreement is an important milestone in the company’s commitment to delivering affordable, life-changing biosimilar medicines. “

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Panacea Biotec hits 52-week high after settling patent dispute with Sanofi

IIL launches pediatric dose of India’s 1st Indigenous Hepatitis A vaccine

Scientists develop novel radiotracer for earlier detection of disease

Leave A Reply Cancel Reply

Current Issue – September 2025
Biotech Express – e-ISSN: 2454-6968

Editorial Board

For Authors – Article Submission and Guidelines

Peer Review Policies

License and Copyright

Advertisement

Recent Posts
  • CDC Boss kicked out in RFK Jr.’s War on Corruption in pharma and healthcare 21/09/2025
  • Prof. Rajeev Varshney FRS, now joins Australian Academy of Science 20/09/2025
  • Dr. Cyrus S. Poonawalla, SII unveiled the newly built School for Hearing Impaired in Pune 19/09/2025
  • AdFalciVax: ICMR’s New Malaria Vaccine: Hope or Premature Hype?” 18/09/2025
  • The Sudden Deaths and COVID Vaccines: A Critical Analysis of the ICMR and AIIMS Studies 17/09/2025
  • KGMU Scandal: Dr. Tulika Chandra Exposed in Crore Rupee Forgery and Scam 16/09/2025
  • Zydus to launch market-specific dosage variants of Semaglutide, MD says 15/09/2025
  • Biocon Biologics Launches Nepexto, Etanercept Biosimilar in Australia 15/09/2025
  • India launched its first National Biofoundry Network 15/09/2025
  • India has 94 Biotech Incubators across 25 states over 13 years 15/09/2025
Archives
Categories
  • Articles
  • Biotech News
  • Controversial
  • Editorials
  • Events
  • Featured
  • Guest Articles
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • News-Industry
  • News-Research
  • Policies
  • SARS- CoV2 & COVID-19 Updates
  • Start-ups
About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Submission Policy and Guidelines

Submission policies

 

 

Follow us on Social Media
  • Facebook
  • Twitter
  • YouTube
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2025 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.